Morning Panels
9:30 am - 10:10 am
Great America 1
The impact of strategic alliances on shaping the pharmaceutical industry is unprecedented, and the trend is here to stay. How is large pharma going about identifying value in the startup arena and what steps can early stage companies take to exploit large pharma’s quest for new technologies and products. This panel will include perspectives from large pharma partnering representatives who will highlight their unique approaches to strategic alliances and discuss case studies of deals involving small biotech and pharma. The panel will enable more informed decisions with respect to identifying synergies, approaching large pharma and structuring successful deals.
Moderator:
Bill Patrick
Funding Available to Startups
9:30 am - 10:10 am
Great America 2
While
venture capital provides startups the much needed capital for product
development, not all companies have what it takes to successfully raise such
financing. VC criteria may not fit a company’s business model and need not
serve as the only resource to bridge the gap between R&D and market
outcomes. Furthermore, The VC environment although much improved from
previous years, especially for early stage technologies, remains saturated
and competitive. This panel seeks to shed light on alternative sources of
financing for early stage technologies including private equity placements,
regulation D financing and foundations and investment groups that provide
funding for technologies targeting significant social issues.
Afternoon Panels
The last year has been a challenging one for investors but there were many promising trends. VC-backed IPO's were up 33% while raising 60% more money than the previous year. VC and Angel funding was on the track to exceed 2006. M&A activity held its own. Funding continued shifting to later stage deals, however there is plenty of money for quality early stage companies. Also, Angel capital associations showed strong growth, individual Angels are returning to the fold, and VCs are making seed and early stage investments. There are more diverse sources of capital for seed and early stage companies. How to find them? How to best position to attract the right kind of capital?
